ImmuCell specializes in developing innovative animal health products aimed at enhancing the immunity and overall health of newborn calves, particularly through their flagship product, First Defense® Tri-Shield™. This product is the only USDA-accredited, colostrum-derived scours preventative that provides Immediate Immunity™ against E. coli, coronavirus, and rotavirus, which are the primary causes of neonatal scours. By delivering specific bovine antibodies that calves cannot produce on their own immediately after birth, First Defense® helps to significantly reduce mortality and morbidity rates associated with scours, a leading cause of death in newborn calves. The product's unique two-part mode of action ensures that antibodies are delivered at the gut level for immediate protection while also circulating in the bloodstream for extended immunity.

In addition to First Defense®, ImmuCell is advancing its Re-Tain™ product, an intramammary treatment for subclinical mastitis, which is a prevalent and costly issue in the dairy industry. This treatment is nearing FDA approval and is designed to provide an effective alternative to traditional antibiotics, eliminating the need for milk discard or meat withholding. By focusing on scientifically-proven methods to prevent disease and reduce antibiotic use, ImmuCell aims to maximize the genetic potential of dairy and beef operations while improving profitability for producers. Their commitment to meeting regulatory standards and providing effective solutions positions them as a leader in the animal health sector.

United States

ImmuCell Corporation is a biotechnology company based out of Portland Maine. ImmuCell's focus is to create scientifically-proven and practical products that result in a measurable economical impact on animal health and productivity in the dairy and beed industries.

ImmuCell

Company Details